.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Cerilliant
Citi
Boehringer Ingelheim
US Department of Justice
Harvard Business School
Cipla
Covington
McKinsey
Accenture

Generated: July 22, 2017

DrugPatentWatch Database Preview

ESBRIET Drug Profile

« Back to Dashboard

What is the patent landscape for Esbriet, and what generic Esbriet alternatives are available?

Esbriet is a drug marketed by Genentech Inc and is included in two NDAs. There are nineteen patents protecting this drug.

This drug has one hundred and ninety-six patent family members in forty countries.

The generic ingredient in ESBRIET is pirfenidone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.

Summary for Tradename: ESBRIET

Patents:19
Applicants:1
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list89
Clinical Trials: see list10
Patent Applications: see list1,713
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ESBRIET at DailyMed

Pharmacology for Tradename: ESBRIET

Ingredient-typePyridones
Drug ClassPyridone
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes7,696,236► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes7,816,383► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-002Jan 11, 2017DISCNYesNo► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes8,420,674► SubscribeY ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes8,754,109► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ESBRIET

Country Document Number Estimated Expiration
Japan2012509362► Subscribe
New Zealand591443► Subscribe
South Korea20120099772► Subscribe
African Regional IP Organization (ARIPO)2655► Subscribe
Peru15022012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Harvard Business School
Cipla
Cantor Fitzgerald
US Army
US Department of Justice
Federal Trade Commission
QuintilesIMS
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot